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DOI: 10.1039/b810227aThe established stability of carbon-paste electrodes (CPEs) in brain extracellular fluid was exploited to
develop a voltammetric technique to monitor the dopamine metabolite, homovanillic acid (HVA), at 10
s intervals. At the scan rates needed for this time resolution, 3,4-dihydroxyphenylacetic acid (DOPAC),
electrogenerated as a result of HVA oxidation, was observed in the cyclic staircase voltammograms,
and this interfered with the straightforward reliable quantification of HVA. However, correction of the
HVA signal, recorded in mixtures, with currents from the DOPAC and ascorbate regions of the
voltammogram allowed the reproducible construction of well behaved HVA calibration plots. These
showed good linearity, LOD values, selectivity and stability during six days of continuous CPE
exposure to a lipid medium, which served as an in-vitro model of CPE implantation in brain tissue for
future applications.Introduction
Dopamine (DA) is a catecholamine neurotransmitter in
a number of brain regions, and is important in the expression of
a wide range of behaviours, including motor control, cognitive
functions and reinforcement emotions.1–4 Indeed, many of the
common drugs of abuse have specific actions on brain DA
reward systems, and this mechanism may be involved in their
addictive properties.5 The ability to monitor a highly temporally
resolved index of DA activity in discrete brain areas over
extended periods, during well defined behaviours and in response
to pharmacological challenges, would provide an important key
to understanding more fully the role this molecule plays in brain
function.
A growing number of in-vivo monitoring (IVM) methodolo-
gies are being developed, including sampling,6,7 spectroscopic8
and electrochemical,9–11 to study neurochemical phenomena in
the intact brain. One subset of these techniques focuses on the in-
situ detection of substances in brain extracellular fluid (ECF),
using in-vivo voltammetry (IVV) with implanted amperometric
electrodes. An important aspect of developing an IVV technique
is the choice of target analyte whose concentration can be used as
a reliable index of neurotransmitter release. The most obvious
candidate for monitoring DA release is the concentration of DA
itself in ECF, resulting from its overflow from the synapse,10 and
a number of successful IVV techniques have been devised to
monitor DA in neurochemical applications.10–16 One problem
with the direct detection of DA is its very low baseline concen-
tration in the ECF (<50 nM17–20), due to efficient DA re-uptakeaUCD School of Chemistry and Chemical Biology, University College
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This journal is ª The Royal Society of Chemistry 2009mechanisms. Thus, the established IVV technique for monitoring
neurotransmitter DA in the ECF with sub-second time resolu-
tion, using fast cyclic voltammetry and carbon fibre electrodes, is
limited to a time range of minutes, because the small DA signal is
overwhelmed by metabolite contamination (mainly 3,4-dihy-
droxyphenylacetic acid, DOPAC) after this time.21DOPAC itself
is considered to be more closely coupled to DA synthesis than
release,22–26 and the very high affinity of the DA re-uptake carrier
for the metabolite 3-methoxytyramine27 precludes the detection
of this potentially useful DA marker in the ECF.28
Detection of another DA metabolite, homovanillic acid
(HVA), using implanted carbon-paste electrodes (CPEs), has
been used in previous studies to investigate DA function.26,29–34
The advantages and limitations of this approach have been
reviewed recently, together with a summary of DA metabolic
pathways.29 The main attraction of the HVA signal recorded
with CPEs is its stability over many weeks of monitoring.35
However, an important drawback with previous IVM studies
involving HVA, including those using microdialysis,36 is the low
sampling frequency, which was of the order of 10–30 min inter-
vals. In the present work, where the emphasis was on the
development of a technique suitable for long-term monitoring of
DA function at high time resolution (seconds), the CPE HVA
signal was the index of choice. The aim was not to compete with
approaches that exploit the detection of DA directly, but rather
to provide a complementary tool for studying DA function over
different time scales.
Here we report the novel observation that DOPAC is electro-
generated from HVA during cyclic voltammetry, and that this
leads to interference in HVA quantification. Correction methods
to compensate for DOPAC and ascorbate interference in HVA
calibrations are also demonstrated as a prerequisite to future in-
vivo characterisation. Many reviews on the complex principles of
IVV (some of which are referred to above) have been published,
and a representative selection is cited here.30,37–49Analyst, 2009, 134, 893–898 | 893
Fig. 1 Sections of cyclic staircase voltammograms at 1 V/s for AA and
HVA in separate experiments, using a CPEPEA in phosphate buffered
saline (PBS, pH 7.4), illustrating that the intrinsic separation (270 mV)
between the rising kinetic waves for these two signals is maintained even
at relatively high scan rates. Background scans have been subtracted in
both cases to eliminate capacitance currents, emphasising the Faradaic
component of the response. A scan-1 section was used for HVA to avoid
DOPAC generation (see Fig. 2 and Fig. 3). Inset: potential of maximum
slope (Es,max) for AA and HVA at both untreated (UN, n¼ 10) and lipid-
treated (PEA, n ¼ 19) CPEs.Experimental
Carbon paste was prepared by thoroughly mixing 2.83 g of
carbon powder (UCP-1-M, Ultra Carbon Corporation, Bay
City, MI) and 1.0 mL silicone oil (Aldrich, Cat. No. 17 563-3).
The CPEs were prepared using approximately 4 cm lengths of
Teflon-coated Ag wire (Advent Research Materials, Eynsham,
England; 370 mm diameter wire). The Teflon insulation was slid
along the wire to create an approximately 1 mm-deep cavity. The
cavity was tightly packed with the paste mixture, using a bare Ag
wire as plunger, and the disk surface smoothed by rubbing gently
on a clean card.
Experiments were carried out in a phosphate buffer saline
(PBS) solution, pH 7.4, containing NaCl (BDH, Poole, Dorset,
UK, AnalaR grade, 0.15 M), NaH2PO4 (BDH, AnalaR grade,
0.04 M) and NaOH (Merck, Darmstadt, Germany, analytical-
reagent grade, 0.04 M). The lipid phosphatidylethanolamine
(PEA, sheep brain cephalin, type II-S, Sigma), homovanillic acid
(HVA, Sigma), 3,4-dihydroxyphenylacetic acid (DOPAC,
Sigma) and L-ascorbic acid (AA, Aldrich) were used as supplied.
100 mM stock solutions of AA, HVA and DOPAC were
prepared using 0.01 M HCl. A 10% PEA suspension was made
by vibrating 0.1 g PEA in 1 mL PBS.
The majority of the working electrodes were treated with the
PEA medium for 24 h (CPEPEA) before being rinsed and
transferred to the electrochemical cell containing 20 mL PBS at
room temperature, together with a saturated calomel reference
electrode (SCE) and a stainless steel needle auxiliary electrode.
The voltammetric experiments were controlled using a low-
noise potentiostat (Biostat IV, ACM Instruments, Cumbria,
UK) linked to a PC through a Biodata Microlink interface
system.
Cyclic staircase voltammograms (CVs) for AA, DOPAC and
HVA in PBS were recorded between 300 and 700 mV vs. SCE
at 1 or 0.2 V/s, using a step size of 10 or 5 mV, unless stated
otherwise. This is a fair approximation to cyclic voltamme-
try;50,51 however, because no rigorous kinetic parameters were
determined in this study, the similarity is fortuitous. Scans were
recorded initially in background electrolyte (PBS) under
continuous mild (1 Hz) stirring conditions to allow the elec-
trodes to condition and equilibrate; aliquots of stock HVA,
DOPAC and AA were then added while recording continued
under the same conditions, which allowed efficient mixing. The
concentration ranges used were appropriate to physio-phar-
macological conditions in vivo: tens of micromolar for the
metabolites,17,52 and hundreds of micromolar for AA.53,54
Averaged background scans, recorded in PBS and comprising
mainly of capacitance currents, were subtracted from voltam-
mograms of analyte in some analyses to highlight the Faradaic
response. This practice is useful when dealing with electrodes
with relatively high double-layer capacitance, such as surfac-
tant-treated CPEs,55,56 and/or voltammetric techniques
employing high scan rates.57,58
Data are reported as mean  SEM, with n ¼ number of
electrodes. The significance of differences observed was esti-
mated using Student’s two-tailed t-tests. Paired tests were used
for comparing signals recorded with the same electrode (e.g.,
before and after a treatment); unpaired tests were used for
comparing responses obtained with different electrodes.894 | Analyst, 2009, 134, 893–898Results and discussion
The presence of AA in relatively high concentrations in brain
ECF (0.5 mM),53 coupled with its low electrode potential,59,60
means that IVV techniques designed to monitor other neuro-
chemical analytes, such as HVA, must be able to separate the AA
and target signals. The long-term stability of CPEs in brain tissue
(up to several weeks of continuous recording)29,35 results from the
ability of brain lipids to protect this electrode surface from
protein fouling,61 and a number of studies have established that
exposing CPEs to lipids such as PEA in vitro, producing CPEPEA,
serves as a good model of the behaviour of CPEs in brain
tissue.56,61–65 In addition, lipids (and other surfactant media)66,67
can remove surface pasting oil from CPEs, enhancing electron
transfer kinetics and improving signal resolution.64 The voltam-
metric behaviour of AA at very slow sweep rates at carbon
electrodes has been described extensively,56,63,68–73 as has that of
HVA under similar conditions,29,30,74,75 and the ability of CPEPEA
to resolve AA and HVA signals recorded at 10 min intervals in
vivo at scan rates as low as 5 mV/s is clear.29,33,76,77 However,
because our aim was to develop a technique to monitor HVA
with a time resolution of the order of seconds, the cyclic vol-
tammetric response of AA andHVA at CPEPEA for a scan rate of
1 V/s was determined, initially in separate solutions (Fig. 1).AA and HVA studied separately
Fig. 1 shows sections of the voltammetric responses for HVA and
AA, recorded separately with a CPEPEA in PBS at 1 V/s. The
oxidation of AA at many electrode materials is irreversible due to
following chemical reactions,78,79 while that for HVA is irre-
versible due to the breaking of the O–C methoxy bond (see
Fig. 2). For clarity, therefore, only the forward (anodic) sweep of
the CV is shown in Fig. 1. When voltammetric waves are broad
or sigmoidal, such as those in Fig. 1, the potential of maximumThis journal is ª The Royal Society of Chemistry 2009
Fig. 2 Electrochemical generation of a reversible redox couple
(DOPAC/4-acetoquinone) from the irreversible oxidation of HVA (step
1), which also requires the addition of a H2O molecule (not shown). The
reversible couple involves the addition of 2H+ and 2e for the formation
of DOPAC (step 2) and their removal upon oxidation (step 3). See Fig. 3
and text for electrochemical evidence for this scheme.slope (Es,max) is superior to the peak potential (Ep) for quanti-
fying the wave position on the voltage axis. Shifts in Es,max
(dEs,max) can therefore be used as an index of changes in the
heterogeneous electron transfer coefficient, ko0, for a given redox
couple on different surfaces determined under the same condi-
tions (pH, temperature, etc.).61,80
The Es,max values (Fig. 1, inset) for AA and HVA at CPEPEA
showed good wave separation (DEs,max ¼ 270  18 mV, n ¼ 19)
at 1 V/s, which compares favourably with peak separation
observed at 5 mV/s in vivo (350 mV),81 considering the 200-fold
difference in scan rates and the irreversible nature of the electro-
oxidations involved. This DEs,max value was statistically better
than that observed at fresh untreated CPEs (149  35 mV, n ¼
10, p < 0.002; see Fig. 1, inset), mainly because the effect of lipidFig. 3 Cyclic staircase voltammograms at 1 V/s for 50 mMHVA in PBS,
using a CPEPEA, illustrating the electrochemical generation of DOPAC
(see Fig. 2). Scan-1 shows the irreversible electro-oxidation of HVA on
the forward sweep, and a small reduction peak for DOPAC on the
backward scan. Scan-2 shows the oxidation of DOPAC (newly formed
fromHVA oxidation at the electrode surface) and a larger reduction peak
for DOPAC on the backward scan due to accumulation of electro-
generated products around the CPEPEA disk surface. Background scans
recorded in PBS have been subtracted to eliminate capacitance currents.
This journal is ª The Royal Society of Chemistry 2009on decreasing Es,max (increasing k
o0) for AA (dEs,max ¼ 311 
36 mV, n ¼ 10) was greater than the corresponding effect on
HVA (190  17 mV, n ¼ 10; p < 0.008). These initial results
indicated that CPEPEA had the ability to resolve AA and HVA
signals recorded at 1 V/s, although this remained to be verified
for mixtures (see below). Before progressing, however, a novel
complication with the electrochemistry of HVA was observed
which could seriously undermine its quantification, i.e., the
electrosynthesis of 3,4-dihydroxyphenylacetic acid (DOPAC)
from HVA on the electrode surface (see Fig. 2 and Fig. 3).HVA oxidation on lipid-treated CPEs
Fig. 3 shows CV scans-1 and -2 at 1 V/s for 50 mMHVA in PBS,
using a CPEPEA and subtraction of averaged background elec-
trolyte scans to eliminate capacitance currents. The forward
(anodic) sweep of scan-1 generated a typical electro-oxidation
response (Fig. 3, wave 1), with an Ep value of 550 mV vs. SCE.
The backward (cathodic) sweep of scan-1, however, generated
a reduction peak (20 mV, wave 2), unexpected for an irre-
versible process (Fig. 2, step 1). A new peak appeared on the
forward sweep of scan-2 (wave 3 at 270 mV) followed by an
augmented HVA wave and cathodic peak (Fig. 3). The current
intensity continued to increase on subsequent scans for the same
50 mM concentration of HVA, indicating adsorption of one or
more electroactive species.
The reaction scheme in Fig. 2 is consistent with the voltam-
metric data shown in Fig. 3. More explicitly, on the first scan,
only HVA is present in the cell and this is electro-oxidised via step
1 (Fig. 2) to produce wave 1 (Fig. 3). The product of step 1 is the
oxidised form of DOPAC, and thus on the backward scan this is
reduced to DOPAC (step 2) to generate wave 2. The DOPAC
thus formed is oxidised on subsequent scans to reform the aceto-
o-quinone and more of this quinone is generated from additional
oxidation of HVA at higher applied potentials. The suggestion
that waves 2 and 3 correspond to electrogenerated DOPAC is in
line with literature data showing that DOPAC and other cate-
chols oxidise at potentials between the Ep for AA and HVA at
CPEPEA.
74,82 To test the DOPAC hypothesis further, aliquots of
either 4-methylcatechol, 3,4-dihydroxyphenylethylamine (dopa-
mine) or DOPAC were injected into the electrochemical cell
during CV recording of HVA. Only added DOPAC produced the
same redox signature as waves 2 and 3 in Fig. 3. Taken together,
these data indicate that DOPAC is produced from HVA electro-
oxidation. It remained to be determined, however, what impact
this would have on the ability of CPEPEA to monitor HVA
unambiguously (see below).HVA calibrations with lipid-treated CPEs
To achieve maximum temporal resolution for the detection of
HVA, CV was carried out 1 V/s in continuous scanning mode,
which gave a scan every 2 s. Fig. 4 shows the time course of the
current at 700 mV in response to injections of aliquots of HVA
into the electrochemical cell. The potential was chosen more
anodic than the Ep value to maximise separation from DOPAC
at lower potentials (see Fig. 3), but not too high to drive the
oxidation of amino acids, such as tyrosine, in later in-vivo
applications. The current at this potential for CVs recorded inAnalyst, 2009, 134, 893–898 | 895
Fig. 4 Calibration time course of the current at the plateau potential for
HVA (700 mV; see Fig. 3) recorded at 2 s intervals using CV at 1 V/s with
a CPEPEA in PBS, illustrating the problem of signal drift and interference
by DOPAC and AA (the Inset highlights the two HVA injections).
Background currents have not been subtracted in this analysis to model
future monitoring conditions in vivo where these values would not nor-
mally be available.background electrolyte only (PBS) was stable and consisted
mainly of capacitance effects (Fig. 4). Injection of 30 mM HVA
caused a step increase in current which continued to drift higher;
a following 50 mM HVA injection repeated this pattern (Fig. 4,
inset).
The irreversibility of HVA oxidation (Fig. 2) would not allow
a build-up of adsorbed HVA on the surface, because all such
molecules would be converted to DOPAC electrochemically by
the end of each scan. Thus, HVA was not directly responsible for
the problem of upward drift in current in Fig. 4. In contrast, the
reversibility of DOPAC electro-oxidation (Fig. 2) suggests that
adsorbed DOPAC molecules could remain bound on the surface
in either oxidation state and, since each scan produced additional
DOPAC, the number of such molecules would increase scan by
scan. Indeed, the adsorption of catechols on carbon electrodes
has been reported widely.83–88 Using different potentials to
quantify the HVA signal produced no major improvement in
either the current drift caused by DOPAC adsorption or inter-
ference caused by DOPAC and AA injected into the cell (see
Fig. 4). The next step was to ascertain whether a correction for
interference by DOPAC and AA could be applied, using currents
from the voltammogram corresponding to these compounds.Fig. 5 Calibrations for HVA, using fine-tuned correction currents from
the AA andDOPAC regions of the voltammogram, recorded at 0.2 V/s at
10 s intervals. Examples for two individual CPEPEA sensors (top) and
averaged normalised values (bottom, n ¼ 5).Interference correction of HVA calibrations
Using the CV characteristics of AA (Fig. 1) and DOPAC (Fig. 3)
at CPEPEA, a variety of corrections of the form IHVA ¼ I700 
ICOR were plotted, where the correction potential varied from
100 to 450 mV. No single value of ICOR was found that could
correct for both the HVA signal drift and the response to added
DOPAC and AA shown in Fig. 4. Because we were attempting to
correct for two interference species, currents of the form IHVA ¼
½(2I700  IDOPAC  IAA) were also explored, with little success.
(The factor of 2 in the I700 term was necessary to balance the large
charging currents of the lipid-modified CPEs.56,63) Some combi-
nations did remove the drifting, but AA injections produced
a step response, or vice versa. Only rarely did a set of corrections
lead to the elimination of both problems simultaneously, and this896 | Analyst, 2009, 134, 893–898was deemed to be inadequate as a reliable technique to monitor
HVA.
To overcome this failure to separate reproducibly the three
signals recorded at 1 V/s, the electrochemical resolution of AA,
DOPAC and HVA was increased by reducing the scan rate to 0.2
V/s. Although this lowered the time resolution to one scan every
10 s, it was still vastly superior to literature values of several
minutes.29 Following calibrations with HVA and the interference
species, the correction potentials were determined by the iterative
method used above for the 1 V/s data. Firstly, IHVA was
approximated by I700, and plotted versus scan number, giving
a graph similar to Fig. 4. Next, IHVA was adjusted with a single
correction (I700  IDOPAC) in such a way as to compensate
approximately for signal drifting. Then I700 was adjusted with
a second single correction (I700  IAA) to compensate approxi-
mately for responses to injected AA. Finally, these two correc-
tions were averaged and values of the potentials for IDOPAC and
IAA fine-tuned to minimise both problems. The final optimum
correction currents were typically obtained in the region of 100
and 250 mV, and so can reasonably be labelled IAA and IDOPAC,
respectively, although the ultimate justification lay phenomeno-
logically in the generation of a near-ideal calibration plot for
HVA (Fig. 5).
Fig. 5 shows that this two-point iterative correction was
successful at the 0.2 V/s scan rate, for both individual CPEPEA
sensors (top) and the averaged normalised response over a small
population of electrodes (n ¼ 5, bottom). Starting the scans in
PBS only, corrected IHVA values showed some residual back-
ground currents, which stabilised by scan 10 (see Fig. 5).This journal is ª The Royal Society of Chemistry 2009
Fig. 6 Stability of calibration slope values for the corrected HVA
response over six consecutive days. The CPEs (n ¼ 4) were exposed to
PEA on each day to model continuous implantation in brain tissue. The
average sensitivity was 2.9  0.5 nA/mM with no significant difference
observed over the 6-day period. Inset: example of a 5-point calibration (0,
10, 20, 50 and 100 mMHVA) illustrating good linearity (R2 ¼ 0.998) over
this physiologically and pharmacologically relevant concentration range.Successive injections of HVA produced rapid, step responses
with no drifting. Subsequent additions of DOPAC (25 mM) and
AA (200 mM) did not affect the corrected signal significantly.Linearity and stability of HVA responses
The baseline concentration of HVA in the ECF of rodent brain
regions receiving a strong dopaminergic input, such as striatum
and accumbens, is of the order of 10 mM.17,89 Using the criterion
of three standard deviations of the background current, the
estimated LOD of CPEPEA electrodes was 3 mM (see Fig. 5),
indicating that both physiological and pharmacological changes
in ECF HVA levels could be detected with this significantly
improved technique.29
The linearity of the HVA response, determined using 5-point
calibrations (see Fig. 6, inset), was excellent, withR2¼ 0.998. The
stability of the response was investigated by treating the same set
of CPEs (n ¼ 4) with the lipid suspension for six consecutive
days, and calibrating daily with HVA. There was no significant
change in HVA sensitivity under these conditions which served
as a model for CPEs chronically implanted in brain tissue
(Fig. 6). The exact value of the calibrated HVA sensitivity in vitro
is not as important as the selectivity and stability of the technique
because factors such as tissue tortuosity in vivo prevent accurate
conversion of calibration data into in-vivo analyte concentra-
tions.90,91Conclusions
The novel complication of adsorption of DOPAC, electro-
synthesised during the voltammetric detection of HVA on lipid-
treated CPEs, precluded reliable monitoring of HVA at 2 s
intervals, using CV at a scan rate of 1 V/s. Decreasing the scan
rate to 0.2 V/s, in combination with two carefully chosen
correction currents, did allow the construction of a useful HVA
signal at 10 s intervals. This represents a significant improvementThis journal is ª The Royal Society of Chemistry 2009on existing temporal resolution values for HVA monitoring,
using either in-vivo voltammetric or microdialysis techniques,
which is of the order of several minutes.
Following specialised training, certification and licensing of
the project, the next step in the development of this technique will
involve implantation of the sensors in specific brain regions.
These electrodes can then be characterised in vivo, using the
microinfusion of compounds directly into the tissue, as well as
pharmacological challenges known to influence AA and DA
metabolism. These studies will be required to ascertain whether
the sensitivity, selectivity and stability of the HVA signal con-
structed here will translate to reliable in-vivo monitoring.Acknowledgements
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